TransPerfect Life Sciences to Present on Use of Artificial Intelligence in Clinical Trials at DIA 2017

NEW YORK–(BUSINESS WIRE)–TransPerfect Life Sciences, a specialized division of TransPerfect, the
world’s largest privately held provider of language and technology
solutions for global business, today announced that it is presenting a
session at the 2017 Drug Information Association (DIA) Annual Meeting,
held June 19-21 in Chicago.

Entitled “Impact of Artificial Intelligence on E-Clinical Technology,”
the presentation, which kicks off a larger panel discussion, will be
given by Vladimir Pyagay, TransPerfect’s Product Manager for the Trial
Interactive e-clinical solution.

“Recent years have witnessed the increase in usage of AI across many
industries,” said TransPerfect Co-CEO Phil Shawe. “The ability to apply
this technology to clinical trials and healthcare has opened new
possibilities for improving workflows and delivering life-changing and
life-saving treatments to market more quickly.”

Co-CEO Liz Elting stated, “The trend toward automation in clinical
trials makes AI a very intriguing tool to consider. It has tremendous
potential to disrupt the e-clinical space and the life sciences industry
at large by increasing the degree to which trial stakeholders can
simplify key tasks involved in bringing new therapies to patients and
customers.”

DIA
Session #108: Artificial Intelligence/Machine Learning
is being
moderated and chaired by Badri Rengarajan, Medical Affairs Lead for
Actelion Pharmaceuticals, and will be held on Monday, June 19 at 11:00
AM CT.

In addition to presenting this session, TransPerfect will also be
exhibiting at DIA, showcasing both its services (Booth #808) and
e-clinical technologies (Booth #911). Visit these adjacent booths to
discuss the latest trends in e-clinical solutions and how they integrate
with TransPerfect’s award-winning trial support services.

Demos for Trial Interactive 9.0 and 9.1 can be scheduled by emailing info@trialinteractive.com
or at http://lifesciences.transperfect.com/dia-demo.

About TransPerfect Trial Interactive

TransPerfect’s Trial Interactive solution provides a collaborative
web-based platform for study start-up and eTMF that enables sponsors,
CROs, IRBs, central laboratories, and other vendors to maintain and
update clinical trial documentation in a secure online environment. With
fully searchable solutions including investigator portals, Trial
Interactive streamlines study timelines and reduces the administrative
burdens of global clinical trials. As part of TransPerfect’s Life
Sciences division, Trial Interactive is dedicated to working with
clients on a global, collaborative level, supporting a wide range of
requirements including e-feasibility, eTMF review/reconciliation,
pharmacovigilance and safety management, endpoint adjudication, and
product licensing and alliance management. For more information on Trial
Interactive, please contact info@trialinteractive.com or
+1 212.400.8848, or visit www.trialinteractive.com.

About TransPerfect

With revenues of over $560 million in the last year, TransPerfect is
the world’s largest privately held provider of language
services
 and technology
solutions
. From offices in over 90 cities on six continents,
TransPerfect offers a full range of services in 170+ languages to
clients worldwide. More than 4,000 global organizations employ
TransPerfect’s GlobalLink® Product
Suite to simplify management of multilingual content. With an
unparalleled commitment to quality and client service, TransPerfect is
fully ISO
9001
and ISO
17100
certified. TransPerfect has global headquarters in New York,
with regional headquarters in London and Hong Kong. For more
information, please visit our website at www.transperfect.com.

Contacts

TransPerfect Life Sciences
Ryan Simper +1 212.689.5555
mediainquiry@transperfect.com